As the Strategy and Operations Support Leader for the Disease Interception Accelerator (DIA), Dave Yazujian drives the development and execution of the DIA strategy, ensuring operational efficiency and effectiveness and integrating input from Janssen Research & Development (R&D), the Johnson & Johnson (J&J) Innovation Centers and the broader J&J enterprise.
Dave joined the DIA with more than 28 years of experience at J&J, serving most recently as Vice President, Strategy and Operations Support Leader, Oncology Therapeutic Area (TA). He brings deep insights in managing end-to-end strategies and operating models that span organizations. As a core member of the Oncology Senior Leadership Team, Dave served as a key partner to the TA Head and the Global Commercial Strategy Leader to ensure the alignment, accountability and focus needed for the effective execution of critical TA strategies to deliver growth. He also represented the TA in cross-TA strategy, portfolio and operations management committees to ensure process consistency and alignment across R&D and partner organizations.
Dave has held leadership positions in Project Management in multiple TAs, including Oncology, Neuroscience and Infectious Disease. With a clinical operations background as a Scientific Programmer and Clinical Research Associate, he also directed all aspects of development, maintenance and support for clinical trials management systems with the R.W. Johnson Pharmaceutical Research Institute.
Dave earned a Bachelor of Science in Experimental Psychology from Susquehanna University and a Master of Science in Psychology from Bucknell University.